BTI
AXSM icon

Blue Trust Inc’s Axsome Therapeutics AXSM Stock Holding History

Blue Trust Inc’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$979 Hold
4
– – ﹤0.01% 2301
2026
Q1 		$676 Hold
4
– – ﹤0.01% 2309
2025
Q4 		$731 Buy
+4
New +$558 ﹤0.01% 2338
2025
Q2 		– Sell
-113
Closed -$13.2K – 2459
2025
Q1 		$13.2K Hold
113
– – ﹤0.01% 1789
2024
Q4 		$9.56K Buy
113
+38
+51% +$3.49K ﹤0.01% 1945
2024
Q3 		$6.04K Buy
75
+27
+56% +$2.36K ﹤0.01% 2348
2024
Q2 		$3.83K Buy
+48
New +$3.55K ﹤0.01% 2277
2024
Q1 		– Sell
-38
Closed -$3K – 2199
2023
Q4 		$3K Buy
+38
New +$2.54K ﹤0.01% 1982

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blue Trust Inc's AXSM Position: Q2 2026 in Review

Blue Trust Inc held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 4 shares worth $979. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Blue Trust Inc first reported a position in AXSM in Q4 2023 and has held it in 8 quarters since. The position peaked at $13.2K in Q1 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Blue Trust Inc held 4 shares of Axsome Therapeutics worth $979 as of Q2 2026.
  • Blue Trust Inc left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #2301 holding.
  • Blue Trust Inc first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Blue Trust Inc's Axsome Therapeutics position peaked at $13.2K in Q1 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.